<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742062</url>
  </required_header>
  <id_info>
    <org_study_id>ApTOLL-FIH-01</org_study_id>
    <nct_id>NCT04742062</nct_id>
  </id_info>
  <brief_title>First in Human Clinical Trial of ApTOLL in Healthy Volunteers</brief_title>
  <official_title>First in Human Dose Ascending, Randomized, Placebo-Controlled Clinical Trial to Assess Tolerability and Pharmacokinetics of ApTOLL in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>aptaTargets S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Science and Innovation Spanish Ministry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anagram</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>aptaTargets S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, first-in-human, dose ascending, randomized, placebo-controlled clinical&#xD;
      study to assess the tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL&#xD;
      is an aptamer able to antagonize TLR4 receptor and, therefore, to reduce the inflammatory&#xD;
      response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I clinical trial is divided in two parts: the first part (part A) is a single dose&#xD;
      escalation study and the second (part B) is a multiple dose study. Both are performed in&#xD;
      healthy volunteers.&#xD;
&#xD;
        -  First part: a single dose, i.v. administration (slow infusion), dose escalation with a&#xD;
           maximum of 7 single dose levels, randomized, double-blind, placebo-controlled (saline&#xD;
           solution), in healthy subjects.&#xD;
&#xD;
        -  Second part: a multiple dose, i.v. administration (slow infusion), randomized,&#xD;
           double-blind, placebo-controlled (saline solution), in healthy subjects.&#xD;
&#xD;
      The main objectives of this study are:&#xD;
&#xD;
        1. To evaluate the tolerability and pharmacokinetic characteristics of ApTOLL in healthy&#xD;
           volunteers, after single dose administration in fasting conditions, following an&#xD;
           ascending dosing scheme.&#xD;
&#xD;
        2. To evaluate the tolerability and pharmacokinetic characteristics of ApTOLL in healthy&#xD;
           volunteers, after multiple dose administration in fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Actual">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events as assessed by CTCAE v4.0</measure>
    <time_frame>From dosing to follow-up (day 15 after dosing)</time_frame>
    <description>Adverse Events that occur during the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration</measure>
    <time_frame>Predose and at different times up to 72 hours post-dose</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration</measure>
    <time_frame>Predose and at different times up to 72 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From screening to follow-up (day 15 after dosing)</time_frame>
    <description>Heart Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From screening to follow-up (day 15 after dosing)</time_frame>
    <description>Blood Presure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From screening to follow-up (day 15 after dosing)</time_frame>
    <description>Respiratory Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From screening to follow-up (day 15 after dosing)</time_frame>
    <description>Body Temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory determinations</measure>
    <time_frame>From screening to follow-up (day 15 after dosing)</time_frame>
    <description>Number of patients with treatment-related alterations coagulation parameters (Protrombine Time (PT) and activated Partial Tromboplastine Time (aPTT))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory determinations</measure>
    <time_frame>From screening to follow-up (day 15 after dosing)</time_frame>
    <description>Number of patients with treatment-related alterations Complement Factors activation determined in blood</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>ApTOLL single dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ApTOLL is administered intravenously in a single ascending dose pattern in seven dose levels (0.7mg - 70mg). Levels 1 - 3 include one subject per level and levels 4 - 7 include six subjects per level (1 sentinel + 5 subjects).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered intravenously during seven dose levels. Levels 1 - 3 include one subject per level and levels 4 - 7 include two subjects per level (1 sentinel + 1 subject).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ApTOLL multiple dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ApTOLL is administered intravenously every eight hours during 24h (21mg). This arm includes six subjects (1 sentinel + 5 subjects).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered intravenously every eight hours during 24h. This arm includes twosubjects (1 sentinel + 1 subject).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ApTOLL</intervention_name>
    <description>ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.</description>
    <arm_group_label>ApTOLL multiple dose</arm_group_label>
    <arm_group_label>ApTOLL single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 mL 0.9% Sodium Chloride solution</description>
    <arm_group_label>Placebo multiple dose</arm_group_label>
    <arm_group_label>Placebo single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects (women without possibility of becoming pregnant) willing and&#xD;
             able to give their written consent to participate in the trial.&#xD;
&#xD;
          2. Healthy subjects aged within: 18 to 55 years (limits included).&#xD;
&#xD;
          3. Clinical history and physical examination results within normality.&#xD;
&#xD;
          4. Vital signs and electrocardiogram without clinically significant pathologic&#xD;
             abnormalities and with QTc (Corrected QT space) values lower than 450 ms.&#xD;
&#xD;
          5. Body weight between 65 and 85 kg, inclusive.&#xD;
&#xD;
          6. BMI (Body Mass Index) between 19.0 and 30.0 kg/m2.&#xD;
&#xD;
          7. No clinically significant abnormalities in haematology, biochemistry, serology (Ag HBV&#xD;
             (Hepatitis B Virus), HCV (Hepatitis C Virus) antibodies, HIV (Human Immunodeficiency&#xD;
             Virus) antibodies) and urine tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any chronic medical condition (such as type 1 diabetes) requiring chronic treatment.&#xD;
&#xD;
          2. Evidence of active infection requiring antibiotic therapy within 14 days prior to&#xD;
             screening.&#xD;
&#xD;
          3. Medical history of vasculitis or any autoimmune disease excluding seasonal allergic&#xD;
             rhinitis and childhood history of atopic dermatitis.&#xD;
&#xD;
          4. Subject having at screening examination a sitting blood pressure more than or equal to&#xD;
             140/90 mm Hg or lower than or equal to 90/50 mmHg.&#xD;
&#xD;
          5. Subject having at screening examination a pulse more than 100 beats per minute or a&#xD;
             body temperature more than 37.7 °C. or a respiratory rate outside the normal range of&#xD;
             (14-20 breath per minute).&#xD;
&#xD;
          6. History of any treatment for cancer within the past 2 years, other than basal cell or&#xD;
             squamous cell carcinoma of the skin.&#xD;
&#xD;
          7. Clinically significant abnormalities in screening laboratory tests.&#xD;
&#xD;
          8. Any prescription, over-the-counter and herbal medications within 10 days prior to&#xD;
             study dosing.&#xD;
&#xD;
          9. Use of an investigational drug within 3 months prior to dosing in this study.&#xD;
&#xD;
         10. Psychiatric history of current or past psychosis, bipolar disorder, clinical&#xD;
             depression, or anxiety disorder requiring chronic medication within the past 5 years.&#xD;
&#xD;
         11. Pregnant or breastfeeding women.&#xD;
&#xD;
         12. History of substance abuse, including alcohol.&#xD;
&#xD;
         13. Smokers.&#xD;
&#xD;
         14. History of substance or drug dependence, or positive urine drug screen at screening&#xD;
             visit.&#xD;
&#xD;
         15. History of head injury.&#xD;
&#xD;
         16. History of sensitivity to any drug.&#xD;
&#xD;
         17. Having donated blood in the last month before start of the study.&#xD;
&#xD;
         18. Any reason or opinion of the investigator that would prevent the subject from&#xD;
             participation in the study.&#xD;
&#xD;
         19. Inability to follow the instructions or an unwillingness to collaborate during the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolores Ochoa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials Unit. Hospital Universitario La Princesa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Department. Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://aptatargets.com</url>
    <description>Biotechnology company specialized in therapeutic aptamers</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>ApTOLL</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All the data from this study are going to be published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

